Latest revenue
$0
as of 2024-09-30
Latest net income
$-10.3M
as of 2024-09-30
Net margin
—
as of 2024-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think CTNM is heading?
Price · 5Y
Market data
Price feed temporarily unavailable for CTNM.
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Item 1. Business. Overview We are a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of NI&I indications with significant unmet need. We target biological pathways associated with specific clinical impairments that we believe, once modulated, will demonstrably alter the course of disease. We focus on developing selective compounds targeting challenging molecular pathways and have built a portfolio of small molecule drug candidates. We believe our two clinical-stage, internally-discovered drug candidates, PIPE-791 and PIPE-307, will have broad applicability across multiple NI&I indications. We are developing PIPE-307 in collaboration with J&J.…
AI summary unavailable — showing raw filing excerpt
Generated from CTNM's filing dated 2026-03-05
Key risks
Table of Contents Item 1A. Risk Factors. RISK FACTORS Investing in our common stock is speculative and involves a high degree of risk. Before investing in our common stock, you should consider carefully the risks and uncertainties described below, together with the other information contained in this report, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and the related notes, before investing in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial…
AI summary unavailable — showing raw filing excerpt
Generated from CTNM's filing dated 2026-03-05
Profitability
Operating margin
-825.4%
44.4%Net margin
-727.4%
53.3%Return on equity
-30.3%
41.9%Return on assets
-21.7%
9.2%Leverage
Debt / equity
0.40×
431.6%Debt / assets
28.4%
309.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-14.5M | +9.6% | — |
Q4 2025 2025-12-31 | — | — | $-15.2M | -4.1% | — |
Q3 2025 2025-09-30 | — | — | $-12.8M | -24.6% | — |
Q2 2025 2025-06-30 | — | — | $-16.0M | -78.0% | — |
Q1 2025 2025-03-31 | — | — | $-16.0M | -90.0% | — |
Q4 2024 2024-12-31 | — | — | $-14.6M | — | — |
Q3 2024 2024-09-30 | $0 | — | $-10.3M | -64.2% | — |
Q2 2024 2024-06-30 | $0 | -100.0% | $-9.0M | -124.5% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on CTNM — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$737.4K
Net activity
−$737.4K
Distinct insiders
3
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns CTNM
Institutional value
$99.2M
Total shares held
7.6M
Distinct holders
25
-54 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | JOHNSON & JOHNSON | 2.0M | $25.8M | -2.0M (-50.0%) | Trimmed |
| 2 | FRANKLIN RESOURCES INC | 1.8M | $24.0M | -40.1K (-2.1%) | Trimmed |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1.2M | $15.9M | — | New |
| 4 | BlackRock, Inc. | 669.1K | $8.7M | +133.0K (+24.8%) | Added |
| 5 | Red Tree Management, LLC | 638.2K | $8.3M | +0 (+0.0%) | No change |
| 6 | Versant Venture Management, LLC | 542.6K | $7.1M | +0 (+0.0%) | No change |
| 7 | UBS Group AG | 230.4K | $3.0M | +31.0K (+15.6%) | Added |
| 8 | VANGUARD FIDUCIARY TRUST CO | 153.9K | $2.0M | — | New |
| 9 | JANE STREET GROUP, LLC | 107.4K | $1.4M | +79.4K (+284.3%) | Added |
| 10 | DIMENSIONAL FUND ADVISORS LP | 59.9K | $782.1K | — | New |
| 11 | Hudson Bay Capital Management LP | 42.8K | $559.2K | +16.9K (+65.1%) | Added |
| 12 | BNP PARIBAS FINANCIAL MARKETS | 39.9K | $520.8K | -24.3K (-37.9%) | Trimmed |
| 13 | INDEPENDENT FINANCIAL GROUP, LLC | 27.0K | $352.9K | — | New |
| 14 | China Universal Asset Management Co., Ltd. | 13.5K | $176.3K | +9.7K (+258.7%) | Added |
| 15 | Cannon Global Investment Management, LLC | 13.0K | $169.8K | — | New |
| 16 | Vanguard Global Advisers, LLC | 10.3K | $134.1K | — | New |
| 17 | CITIGROUP INC | 8.9K | $115.7K | -3.5K (-28.1%) | Trimmed |
| 18 | JPMORGAN CHASE & CO | 2.5K | $31.0K | +696 (+38.8%) | Added |
| 19 | Mirae Asset Global Investments Co., Ltd. | 1.6K | $20.7K | +466 (+41.5%) | Added |
| 20 | GF FUND MANAGEMENT CO. LTD. | 513 | $6.7K | +59 (+13.0%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once CTNM's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.